ANAVEX2-73-AD-004 EP (Phase 2b/3)

Drug Development Trials

About the trial

A phase 2B /3 open-label extension to confirm the safety and efficacy of Sigma-1 in subjects with early Alzheimer’s disease.

The medication aims to restore cellular balance by targeting sigma-1 and muscarinic receptors. It is administered by oral tablet once a day.